Inhibitory effect of statins on renal epithelial-to-mesenchymal transition

Sharmila Patel1, Roger M Mason, Jun Suzuki

  • 1Teijin Biomedical Laboratory, Medical Research Council Technology, London, UK.

Abstract

Insights

Statins inhibit kidney cells from transforming into fibrotic cells by blocking RhoGTPase activation. This mechanism may explain statins' protective effects against renal fibrosis.

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Statins may offer renal protection beyond cholesterol reduction.
  • RhoGTPase activation drives epithelial-to-mesenchymal transition (EMT) and renal fibrosis.

Purpose of the Study:

  • To investigate if statins inhibit EMT by targeting RhoGTPase isoprenylation.
  • To explore the mechanism of statin-induced renal protection.

Main Methods:

  • Used human proximal tubular epithelial cells (HK2).
  • Induced EMT using conditioned medium from activated peripheral blood mononuclear cells.
  • Assessed statin effects on EMT markers and RhoGTPase activation.

Main Results:

  • Lovastatin, simvastatin, and pravastatin inhibited HK2 cell EMT.
  • Statins reduced RhoA and Rac1 activation, preserved epithelial markers (E-cadherin, cytokeratin-19), and decreased myofibroblast marker (Fn-EDA).
  • Reversal of RhoGTPase inhibition by geranylgeranyl pyrophosphate confirmed isoprenylation blockade.

Conclusions:

  • Statins inhibit RhoGTPase activation, preventing EMT in kidney cells.
  • This mechanism offers a potential explanation for statins' renoprotective effects against fibrosis.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...